Lipid‐Based Amphotericin B for the Treatment of Fungal Infections

@article{Slain1999LipidBasedAB,
  title={Lipid‐Based Amphotericin B for the Treatment of Fungal Infections},
  author={Douglas Slain},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={1999},
  volume={19}
}
  • D. Slain
  • Published 1 March 1999
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
The frequency of life‐threatening fungal infections has increased dramatically over the past few decades. For more than 30 years amphotericin B has been the standard treatment for systemic and deep‐seated fungal infections, primarily because of its broad spectrum of activity. Its usefulness is limited by a relatively high frequency of significant adverse events including infusion‐related reactions and nephrotoxicity. In an effort to overcome these side effects, a number of lipid‐based… 
Amphotericin B use in children: conventional and lipid-based formulations
  • N. Kuyucu
  • Biology, Medicine
    Expert review of anti-infective therapy
  • 2011
TLDR
While less frequently employed today as prophylaxis (given the expanded availability of safer alternatives), amphotericin B is still considered a treatment option in select cases of severe or life-threatening IFIs.
Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses
TLDR
Progress over the last decade in understanding the pharmacology and clinical dosing of AMB formulations for common systemic mycoses, including invasive candidiasis, cryptococcosis, aspergillosis and mucormycosis is reviewed.
Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity
TLDR
The few comparative clinical trials that have been completed with the lipid-associated formulations have not demonstrated important clinical differences among these agents and amphotericin B for efficacy, although there are significant safety benefits of the lipid products.
Polyene Antifungal Agents
TLDR
Insight into the pharmacokinetic/pharmacodynamic behaviour of the polyenes suggest a limited role for dosage escalation in the treatment of invasive pulmonary aspergillosis, and the continued development of new formulation approaches and interest in aerosolised delivery strategies may open new opportunities for the use of polyenes.
Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions
TLDR
The present article reviews incidence, severity and mechanisms of nephrotoxicity associated with antifungal agents used for prevention and treatment of invasive fungal diseases by discussing distribution, metabolism, elimination and drug-related adverse events in the context of safety data from phase II and III clinical studies.
[New developments in therapy of deep mycoses].
  • H. Yamaguchi
  • Biology, Medicine
    Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology
  • 2000
TLDR
There is an urgent need to develop new antifungal agents or formulations with advantages over and/or complimentary to existing drugs, including lipid formulations of amphotericin B, second-generation azoles and antifunkal lipopeptides.
Amphotericin B-Induced Nephrotoxicity: A Review
TLDR
To provide optimal patient care, it is imperative that the clinician understand the etiology of and the signs and symptoms associated with nephrotoxicity, as well as interventions to prevent neph rotoxicity in patients receiving amphotericin B.
Newer antifungal agents
TLDR
The Lipid-based amphotericin B, Voriconazole (a new azole), and Caspofungin (an echinocandin) are discussed, which are considered to be new approaches to antifungal treatment.
Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients.
TLDR
The pharmacokinetic profiles and non-compartmental parameters calculated were comparable for both patients diagnosed with acute myeloblastic leukemia after multiple dosing at steady state, which demonstrated a twofold increase in their AUC values compared with the AUC of the first patient.
Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: a retrospective study.
TLDR
Data from this study suggest that ABLC infrequently causes clinically significant nephrotoxicity, and formulary decisions are made in the selection of a drug for use in various clinical settings should be interpreted cautiously.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 154 REFERENCES
Lipid formulations of amphotericin B.
TLDR
The clinical data indicate that lipid formulations of amphotericin B represent an important therapeutic modality in the management of invasive fungal infections.
Amphotericin B: 30 years of clinical experience.
TLDR
The clinical uses of amphotericin B are discussed, including its application in AIDS-related fungal infections, in neutropenic cancer patients who are persistently febrile, and in infections of the central nervous system, lung, peritoneum, genitourinary system, eye, and skin.
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
  • T. Walsh, J. Hiemenz, +9 authors E. Anaissie
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
TLDR
Findings support the use of ABLC in the treatment of invasive fungal infections in patients who are intolerant of or refractory to conventional antifungal therapy.
Amphotericin B: an introduction.
  • D. Warnock
  • Biology, Medicine
    The Journal of antimicrobial chemotherapy
  • 1991
TLDR
There have been no controlled trials to support the use of drug combinations in human infections, apart from one report that the combination with flucytosine is superior to amphotericin B on its own in the treatment of cryptococcal meningitis.
New methods of delivery of amphotericin B.
  • H. Schmitt
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1993
TLDR
Prophylactic administration of low doses of amphotericin B as an aerosol was the most effective of the regimens tested in an animal model of pulmonary aspergillosis and was also judged to be effective in a clinical trial using historical controls.
Treatment of systemic fungal infections with liposomal amphotericin B.
TLDR
Liposomal amphotericin B therapy was effective and less toxic than conventional amphoteric in B therapy and no chronic renal, hematologic, or central nervous system side effects were observed.
Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant.
TLDR
Amphotericin B colloidal dispersion was safe at doses to 7.5 mg/kg and had tolerable-infusion-related toxicity and demonstrable antifungal activity and it was found that patients with fungemia and pneumonia had complete or partial responses to ABCD.
Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.
  • P. Sharkey, J. Graybill, +14 authors D. Gordon
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1996
TLDR
Preliminary data suggest ABLC has significant activity in patients with AIDS-associated cryptococcal meningitis and because this formulation has less hematologic and renal toxicity than does AmB, further evaluation of ABLC is warranted.
The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses.
TLDR
Preliminary evidence is provided that ABCD is effective in treating invasive mycoses and lacks the dose-limiting nephrotoxicity of CAB.
Intralipid in Prophylaxis of Amphotericin B Nephrotoxicity
TLDR
Administration of liposomal formulations of AB has shown a reduction in nephrotoxicity in animals, and the development of a formulation of AB 50 mgllipid 30 mg for clinical use is proposed.
...
1
2
3
4
5
...